Two new "super Gleevec" drugs are nearing the market--dasatinib from Bristol-Myers Squibb and nilotinib from Novartis.

FORBES: Magazine Article

Two new "super Gleevec" drugs are nearing the market--dasatinib from Bristol-Myers Squibb (nyse: BMY - news - people ) and nilotinib from Novartis.

FORBES: The Race Is On

Novartis' nilotinib is close behind.

FORBES: Magazine Article